The Notch pathway inhibits TGF-{beta} signaling in breast cancer through HEYL-mediated crosstalk

Acquired resistance to transforming growth factor-β (TGF-β) is a key step in the early stages of tumorigenesis. Mutations in TGF-β signaling components are rare, and little is known about development of resistance in breast cancer. On the other hand, an activated Notch pathway is known to play a substantial role in promoting breast cancer development. Here, we present evidence of crosstalk between these two pathways through HEYL. HEYL, a basic helix-loop-helix (bHLH) transcription factor and a direct target of Notch signaling, is specifically overexpressed in breast cancer. HEYL represses TGF-β activity by binding to TGF-β-activated Smads. HeyL-/- mice have defective mammary gland development with fewer terminal end buds. On the other hand, HeyL transgenic mice show accelerated mammary gland epithelial proliferation and 24% of multiparous mice develop mammary gland cancer. Therefore, repression of TGF-β signaling by Notch acting through HEYL may promote initiation of breast cancer.